U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H22N6O2.2ClH.H2O
Molecular Weight 505.397
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Momelotinib dihydrochloride monohydrate

SMILES

O.Cl.Cl.O=C(NCC#N)C1=CC=C(C=C1)C2=NC(NC3=CC=C(C=C3)N4CCOCC4)=NC=C2

InChI

InChIKey=RQKCPSIFARJBOR-UHFFFAOYSA-N
InChI=1S/C23H22N6O2.2ClH.H2O/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29;;;/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28);2*1H;1H2

HIDE SMILES / InChI

Molecular Formula C23H22N6O2
Molecular Weight 414.4598
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19295546 | https://www.ncbi.nlm.nih.gov/pubmed/23459451

Momelotinib (CYT387) is an ATP-competitive small molecule that potently inhibits JAK1/JAK2 kinases. Momelotinib is developing by Gilead Sciences for the oral treatment of pancreatic and non-small cell lung cancers, and myeloproliferative disorders (including myelofibrosis, essential thrombocythaemia and polycythaemia vera).

CNS Activity

Curator's Comment: Momelotinib (CYT387) is brain penetrant in mice. No human data available.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
11.0 nM [IC50]
18.0 nM [IC50]
Conditions
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 5.8048 uM]
Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
2017 Feb
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
2017 Jan
Patents

Sample Use Guides

150-300 mg/day. Maximum tolerated dose of momelotinib was found to be 300 mg/day in the phase I portion of a phase I/II study (NCT00935987) in patients with myelofibrosis. At the higher dose level of 400 mg/day, two of six patients experienced dose-limiting toxicities.
Route of Administration: Oral
0.5 and 1.5 uM CYT387 caused growth suppression and apoptosis in JAK2-dependent hematopoietic cell lines, while nonhematopoietic cell lines were unaffected.
Substance Class Chemical
Created
by admin
on Sat Dec 16 18:54:41 GMT 2023
Edited
by admin
on Sat Dec 16 18:54:41 GMT 2023
Record UNII
LDX8893L5D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Momelotinib dihydrochloride monohydrate
Common Name English
CYT-387 DIHYDROCHLORIDE MONOHYDRATE
Code English
MOMELOTINIB HYDROCHLORIDE HYDRATE
Common Name English
Benzamide, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-, hydrochloride, hydrate (1:2:1)
Systematic Name English
CYT-11387 DIHYDROCHLORIDE MONOHYDRATE
Code English
MOMELOTINIB HYDROCHLORIDE HYDRATE [JAN]
Common Name English
OJJAARA
Brand Name English
Code System Code Type Description
PUBCHEM
102514733
Created by admin on Sat Dec 16 18:54:41 GMT 2023 , Edited by admin on Sat Dec 16 18:54:41 GMT 2023
PRIMARY PUBCHEM
CAS
1841094-17-4
Created by admin on Sat Dec 16 18:54:41 GMT 2023 , Edited by admin on Sat Dec 16 18:54:41 GMT 2023
PRIMARY
FDA UNII
LDX8893L5D
Created by admin on Sat Dec 16 18:54:41 GMT 2023 , Edited by admin on Sat Dec 16 18:54:41 GMT 2023
PRIMARY
NCI_THESAURUS
C201546
Created by admin on Sat Dec 16 18:54:41 GMT 2023 , Edited by admin on Sat Dec 16 18:54:41 GMT 2023
PRIMARY
SMS_ID
100000184153
Created by admin on Sat Dec 16 18:54:41 GMT 2023 , Edited by admin on Sat Dec 16 18:54:41 GMT 2023
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY